Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783596 · ClinicalTrials.gov registry record · Phase 2
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
A Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Reid Merryman, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 4
- Study locations
NCT05783596: Active Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Reid Merryman, MD.
NCT05783596 is a Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma that is active but no longer recruiting, run by Reid Merryman, MD. The registered enrollment target is 47 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (65% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05783596, a Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, is active but no longer recruiting, sponsored by Reid Merryman, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Glofitamab (a type of immunotherapy) * Obinutuzumab (a type of immunotherapy)
Primary Outcome
EOT CMR rate defined as the proportion of participants achieving CR per PET/CT Lugano 2014 criteria (protocol appendix B) at the EOT assessment: PET-CT, score 1, 2, or 3 with or without a residual mass on a 5-point scale (5PS).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Columbia University Irving Medical Center - New York
- Mount Sinai Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2029-08 |
| Phase | Phase 2 |
What the registry record for NCT05783596 still lists
NCT05783596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT05783596 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05783596 about?
NCT05783596 is a clinical study titled "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma". The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in ...
What is the current status of trial NCT05783596?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2023-07-18. Estimated completion is 2029-08.
What conditions does trial NCT05783596 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05783596?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG).
Who is sponsoring clinical trial NCT05783596?
This trial is sponsored by Reid Merryman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05783596 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05783596's enrollment target sits among peer trials
47 47th of 89 higher than 43 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI